GLP-1 & E-Cigarette Public Health Narratives
Two evidence-backed health threads are gaining traction: GLP-1 obesity drugs almost didn't reach patients due to corporate stigma, and e-cigarettes may have saved thousands of American lives after a 2010 court ruling.
What we know
An account on X RTs his own thread on how Novo Nordisk management resisted getting GLP-1 drugs approved for obesity treatment due to internal stigma, requiring researchers to repeatedly push the agenda. Separately, he highlights how a 2010 court ruling exempted e-cigarettes from drug regulation, spurring innovation and potentially saving thousands of lives. Both threads challenge the common assumption that regulatory/corporate caution is always protective — and both are gaining RT traction (61 and 66 RTs respectively).
By the Global Eye 24 desk, with AI assistance. Updated as the story develops. Spot an error? Write to corrections@globaleye24.com.